Psychedelic-assisted psychotherapy and its potential to manage demoralization: A brief exploration of an alternative approach to end of life care
OpenAlex – May 07, 2025
Source: OpenAlex
Summary
Australia has made a landmark decision in Medicine, becoming the first country to approve specific psychedelics for clinical use. Psychotherapists can consider MDMA for post-traumatic stress disorder and psilocybin for treatment-resistant depression, a significant step in Psychology. This move opens new avenues in Psychedelics and Drug Studies. Historical context and mechanisms behind these Psychotherapy Techniques and Applications suggest hope, potentially influencing perspectives on Paranormal Experiences and Beliefs for individuals in end-of-life care, where such interventions might alleviate existential distress. This development could reshape therapeutic approaches.
Abstract
Australia has become the first country to approve the use of psychedelics, namely MDMA and psilocybin, for clinical treatment of post-traumatic stress disorder and treatment-resistant depression. Here, we briefly explore the history of its use, how it works, and the hope it may provide people receiving end-of-life care.